Clinical Trials Logo

Acute Disease clinical trials

View clinical trials related to Acute Disease.

Filter by:

NCT ID: NCT02879981 Completed - Bronchitis Clinical Trials

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Start date: November 10, 2016
Phase:
Study type: Observational

This pilot, multicentric and observational study will assess the safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants with acute bronchitis. Administration of treatment will be according to treating physician's recommendation under local labeling.

NCT ID: NCT02823132 Completed - Acute Leukemia Clinical Trials

Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia

MBL INFFONG
Start date: n/a
Phase: N/A
Study type: Observational

The aim of this study is to investigate levels of a protein, mannose binding lectin, in patients with acute leukemia who develop or not an invasive fungal infection.

NCT ID: NCT02792946 Completed - Acute Bronchitis Clinical Trials

Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis

Start date: November 2015
Phase: Phase 3
Study type: Interventional

Compare the efficacy and safety of surfolase CR tablet with surfolate capsule in patients with acute bronchitis

NCT ID: NCT02693899 Completed - Acute Leukemia Clinical Trials

Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia

FLAM/FLAL
Start date: May 27, 2016
Phase:
Study type: Observational

Despite advances in their classification and treatment, acute leukemia remain incurable disease for the majority of patients. It is necessary to identify new prognostic markers of survival and new therapeutic targets to improve prognosis. Some studies have shown that Fms-like tyrosine kinase 3-ligand (FLT3-L) could be interesting from this. A more recent study from our group testing a novel therapy in acute lymphoblastic leukemia, showed an increase of this marker in the blood of patients responding to treatment. The aim of our prospective, non-interventional study is to measure the plasma levels of FLT3-L at different times of the management of patients with acute lymphoblastic leukemia but also myeloid. For this, analyzes of the samples collected in the usual care will be conducted to study the relationship between the plasma concentration of FLT3-L and outcomes. If there is any link, the FLT3-L could serve as a predictor of treatment response.

NCT ID: NCT02673528 Completed - Acute Appendicitis Clinical Trials

Laparoscopic Assisted or Total Laparoscopic Appendectomy

Start date: January 2015
Phase: N/A
Study type: Observational

Acute appendicitis (AA), is a common intra-abdominal surgical pathology with the overall incidence of approximately 7% and mortality of 0.2-0.8%. Treatment of choice is the surgical removal of the inflamed appendix by using open or laparoscopic appendectomy. Following laparoscopic appendectomy (LA) proved to be a feasible and at least as safe as the corresponding open procedure, it has rapidly gained worldwide acceptance. The traditional approach to LA uses three ports. Over the past decade, successful attempts to perform the procedure with fewer ports have been reported. The authors' primary objectives were to 1) identify a simple, safe and feasible way to perform laparoscopic appendectomy in patients with uncomplicated acute appendicitis. 2) determine the health related quality of life of the patients and calculate the cost per quality adjusted life years (QALYs) gained after the procedures (LAA and TLA). 3) Purpose a surgical algorithm when approaching to acute appendicitis with the consideration of quality of health and cost.

NCT ID: NCT02637310 Completed - Acute Bronchitis Clinical Trials

Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis

Start date: December 2015
Phase: Phase 2
Study type: Interventional

A multi center, randomized, double-blind, placebo-controlled, parallel, phase 2b clinical trial to evaluate the efficacy and safety of N02RS1 in patients with acute bronchitis

NCT ID: NCT02631811 Completed - Clinical trials for Acute Leukaemia in Relapse

Early Palliative Care in Patient With Acute Leukaemia

Pablo Hemato
Start date: February 9, 2016
Phase: N/A
Study type: Interventional

Several studies have shown that patients with acute leukemia have many symptoms during disease These symptoms decrease the quality of life and may even appear or worsen other symptoms such as depression Several studies point to the involvement of supportive care and palliative care is delayed in these patients The aim of this study is to evaluate the impact on the quality of life of an early and standardized involvement of a support / palliative care team for patients with acute leukemia in first relapse compared to a control group .

NCT ID: NCT02580071 Completed - Acute Leukemia Clinical Trials

Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients

Start date: October 2015
Phase: N/A
Study type: Interventional

The treatment options for high-risk acute leukemia patients are limited and these patients are often opt for hematopoietic stem cell transplant (HSCT). However studies show that prognosis following this last-resort therapy is bleak. At times, less than 70% of post-HSCT relapsed AML and ALL patients even achieve complete remission; median overall survival of these cohorts might not reach one year; and 3-year post-HSCT survival rates might be less than 20%. The investigators plan to recruit acute leukemia patients from CMUH which are planned to receive HSCT, and follow the rate and quality of their immune reconstitution. As intervention, part of the patients will receive a Chinese medicine herbal formula, which they will take for 6 months.Differences between the 1-year post-HSCT condition of patients will be examined.

NCT ID: NCT02568475 Completed - Chronic Disease Clinical Trials

Involving Nursing Home Residents and Their Families in Acute Care Transfer Decisions

Start date: October 2012
Phase: N/A
Study type: Interventional

This study addresses the Patient-Centered Outcomes Research Institute (PCORI) area of interest related to development of decision support tools that bring patients, families and clinicians together to decide, in this instance, whether or not transfer from the nursing home (NH) to acute care is necessary and appropriate. The purposes of this study were 1) to develop an evidence-based decision aid addressing potentially avoidable transfers of residents from nursing homes to hospitals (preceded this protocol), and 2) to evaluate this decision aid in terms of acceptability to residents and families and its effect on the quality of transfer decisions. The primary hypotheses to be tested are: Hypothesis 1: Resident and family members in the intervention group will report greater preparation for decision making and less decisional conflict than those in the no treatment control group. Hypothesis 2: Residents and family members in the intervention group will demonstrate increased knowledge related to acute care transfer and less preference for acute care transfer than those in the no treatment control group.

NCT ID: NCT02551718 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Start date: September 11, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). A high throughput screening assay tests many different drugs individually or in combination that kill leukemia cells in tiny chambers at the same time. High throughput drug sensitivity assay and mutation analysis may help guide the choice most effective for an individual's acute leukemia.